Costs and benefits of cervical screening IV: valuation by women of the cervical screening programme
- PMID: 11843938
- DOI: 10.1046/j.1365-2303.2001.00358.x
Costs and benefits of cervical screening IV: valuation by women of the cervical screening programme
Abstract
Objectives: To assess the value of the cervical smear test to women, taking account of the positive and negative aspects of the cervical screening service.
Design: A postal survey.
Setting: Tayside Health Board region of Scotland.
Participants: A sample of 2000 women aged 20-59.
Main outcome measures: Maximum willingness to pay (WTP) for a cervical smear test.
Results: Women were prepared to pay 50.20 British pounds per smear on a 3-yearly basis. Willingness to pay was positively related to income, but unrelated to age and whether or not the respondent had previously had a smear.
Conclusions: Previous studies have estimated the cost per screen or cost per life year saved by cervical screening. This study used the economic instrument of WTP to take account of other potential (dis)benefits to women. The value women place on having a smear was more than the cost to the National Health Service (NHS) of providing the service. The output of a WTP study is potentially useful at the policy level. Future work should explore both the value of alternative approaches to cervical screening, and the value of competing health care interventions.
Similar articles
-
Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women.Cytopathology. 1996 Aug;7(4):249-55. doi: 10.1046/j.1365-2303.1996.40182401.x. Cytopathology. 1996. PMID: 8853971
-
Costs and benefits of cervical screening. I. The costs of the cervical screening programme.Cytopathology. 1996 Aug;7(4):231-40. doi: 10.1046/j.1365-2303.1996.39982399.x. Cytopathology. 1996. PMID: 8853969
-
Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.J Eval Clin Pract. 2011 Dec;17(6):1050-8. doi: 10.1111/j.1365-2753.2010.01453.x. Epub 2011 Jun 16. J Eval Clin Pract. 2011. PMID: 21679279
-
Cost-effective policies for cervical cancer screening. An international review.Pharmacoeconomics. 1996 Mar;9(3):211-30. doi: 10.2165/00019053-199609030-00004. Pharmacoeconomics. 1996. PMID: 10160098 Review.
-
[Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].Rev Med Liege. 1998 May;53(5):305-7. Rev Med Liege. 1998. PMID: 9689888 Review. French.
Cited by
-
Women's Preference for Cervical Cancer Screening Methods in Iran: A Contingent Valuation Survey.Med J Islam Repub Iran. 2022 Jun 30;36:72. doi: 10.47176/mjiri.36.72. eCollection 2022. Med J Islam Repub Iran. 2022. PMID: 36128303 Free PMC article.
-
A review of studies examining stated preferences for cancer screening.Prev Chronic Dis. 2006 Jul;3(3):A75. Epub 2006 Jun 15. Prev Chronic Dis. 2006. PMID: 16776876 Free PMC article.
-
Willingness to pay for adverse drug event regulatory actions.Pharmacoeconomics. 2011 Nov;29(11):963-75. doi: 10.2165/11539860-000000000-00000. Pharmacoeconomics. 2011. PMID: 21910513
-
Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel.Isr J Health Policy Res. 2024 Feb 19;13(1):9. doi: 10.1186/s13584-024-00594-z. Isr J Health Policy Res. 2024. PMID: 38374060 Free PMC article.
-
Cancer patients' willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network.Eur J Health Econ. 2012 Jun;13(3):289-300. doi: 10.1007/s10198-011-0328-9. Epub 2011 Jun 10. Eur J Health Econ. 2012. PMID: 21660563
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical